Blueprint Medicines Corporation EBITDA 2011-2026 | BPMC

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Blueprint Medicines Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
16.3 M	11.7 M	11.7 M	6.48 M	6.56 M	-356 M	-243 M	-150 M	-71 M	-50.7 M	-39.2 M	-20.3 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
16.3 M	-356 M	-73.1 M

Quarterly EBITDA Blueprint Medicines Corporation

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.46 M	-	-	-	4.81 M	-	-	-	3.68 M	-	4.72 M	-	1.63 M	-	4.82 M	1.6 M	1.61 M	-	4.89 M	3.24 M	1.57 M	-	3.68 M	2.39 M	1.18 M	-	3.08 M	1.91 M	780 K	-	1.19 M	791 K	398 K	-	1.19 M	782 K	386 K	-	615 K	411 K	209 K	-	416 K	273 K	134 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.89 M	134 K	1.96 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Graybug Vision GRAY	-23.1 M	-	-11.23 %	$ 9.65 M	USA
AbCellera Biologics ABCL	-199 M	$ 3.7	-0.27 %	$ 1.11 B	Canada
ADMA Biologics ADMA	199 M	$ 16.5	0.73 %	$ 3.93 B	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
ANI Pharmaceuticals ANIP	68.3 M	$ 76.81	0.93 %	$ 1.48 B	USA
Apellis Pharmaceuticals APLS	57 M	$ 20.08	-0.42 %	$ 2.53 B	USA
Aptorum Group Limited APM	1.19 M	$ 0.83	4.23 %	$ 4.53 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	-49.5 M	-	-	$ 521 M	USA
Brainstorm Cell Therapeutics BCLI	-11.5 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	242 M	$ 8.36	-2.22 %	$ 1.39 B	Britain
Axsome Therapeutics AXSM	-166 M	$ 164.46	0.25 %	$ 8.18 B	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
BridgeBio Pharma BBIO	-518 M	$ 66.75	3.44 %	$ 12.8 B	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 2.84	1.07 %	$ 908 M	Israel
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-22.2 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
BioMarin Pharmaceutical BMRN	489 M	$ 60.85	3.96 %	$ 11.7 B	USA
Clovis Oncology CLVS	-217 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
CTI BioPharma Corp. CTIC	-77.8 M	-	-	$ 1.2 B	USA
CohBar CWBR	-12.3 M	-	-15.44 %	$ 2.2 M	USA
Cyclacel Pharmaceuticals CYCC	-12 M	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	-12 M	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	-209 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Cabaletta Bio CABA	-73.2 M	$ 3.41	4.77 %	$ 3.98 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Capricor Therapeutics CAPR	-23 M	$ 26.23	1.51 %	$ 702 M	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Codexis CDXS	-53.6 M	$ 1.1	12.24 %	$ 80.7 M	USA
Certara CERT	96.2 M	$ 7.35	1.45 %	$ 1.18 B	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Entasis Therapeutics Holdings ETTX	-52.2 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	-17.4 M	-	7.55 %	$ 38.1 M	USA